Prosecution Insights
Prosecution Insights
19 pending office actions • 13 clients • 17 examiners • 14 art units • 0 of 19 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (11%) |
| §103 only | 2 (11%) |
| §112 only | 2 (11%) |
| Double-patenting only | 2 (11%) |
| Double-patenting + other | 5 (26%) |
| Multi-statute (no §101) | 6 (32%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DUFFY, PATRICIA ANN | 2 | 52.7% | +34.2% |
| DAVIS, RUTH A | 2 | 60.8% | +31.2% |
| MOU, LIYUAN | 1 | 43.5% | +57.7% |
| ANGELL, JON E | 1 | 70.9% | +21.1% |
| HUDSON, AMY ROSE | 1 | 75.0% | +11.4% |
| GAN, CHUEN-MEEI | 1 | 81.9% | +41.3% |
| SHOWALTER, ALEXANDER KEITH | 1 | 53.6% | +32.5% |
| NATARAJAN, MEERA | 1 | 62.3% | +17.6% |
| PAGUIO FRISING, MICHELLE F | 1 | 70.8% | +40.5% |
| BREEN, KIMBERLY CATHERINE | 1 | 24.4% | +56.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18258914 | HOMOGENEOUS BIOPOLYMER SUSPENSIONS, PROCESSES FOR MAKING SAME AND USES THEREOF | BABSON, NICOLE PLOURDE | 79d overdue |
| 19086136 | FIVE-MEMBERED-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | MOU, LIYUAN | 9d |
| 17759674 | TREATMENT OF SKIN CONDITIONS | DAVIS, RUTH A | 40d |
| 19423511 | CHIMERIC NEUROTOXINS | DUFFY, PATRICIA ANN | — |
| 19341888 | CHIMERIC NEUROTOXINS | DUFFY, PATRICIA ANN | — |
| 18599808 | FATTY ACID CONJUGATES OF NUCLEIC ACIDS | HUDSON, AMY ROSE | — |
| 18573361 | METHOD OF PERFORMING A NUMERICAL SOLVING PROCESS | GAN, CHUEN-MEEI | — |
| 18552599 | Clostridial Neurotoxins Comprising an Exogenous Activation Loop | BREEN, KIMBERLY CATHERINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19086136 | FIVE-MEMBERED-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | MOU, LIYUAN | 9d |
| 18506625 | MACROCYCLIC COMPOUNDS AND USES THEREOF | SHOWALTER, ALEXANDER KEITH | 12d |
| 18096899 | TREATMENT OF MODERATE TO VERY SEVERE GLABELLAR LINES AND LATERAL CANTHAL LINES | DAVIS, RUTH A | 34d |
| 17759674 | TREATMENT OF SKIN CONDITIONS | DAVIS, RUTH A | 40d |
| 19423511 | CHIMERIC NEUROTOXINS | DUFFY, PATRICIA ANN | — |
| 19341888 | CHIMERIC NEUROTOXINS | DUFFY, PATRICIA ANN | — |
| 18812463 | COMPOSITIONS AND METHODS FOR TREATMENT OF BLEEDING DISORDERS | ANGELL, JON E | — |
| 18599808 | FATTY ACID CONJUGATES OF NUCLEIC ACIDS | HUDSON, AMY ROSE | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Ipsen | 6 |
| Band Therapeutics, LLC | 2 |
| Hangzhou Polymed Biopharmaceuticals | 1 |
| Guardian Therapeutics, LLC | 1 |
| Talos Innovation Aps | 1 |
| Theseus Pharmaceuticals, Inc. | 1 |
| Zenyth Operations Pty. Ltd. | 1 |
| 11584022 CANADA INC. | 1 |
| Xencor | 1 |
| Imcheck Therapeutics SAS | 1 |
| VISTERRA, INC. | 1 |
| Beam Therapeutics Lnc. | 1 |
| Praeventix, LLC | 1 |
| Art Unit | Apps |
|---|---|
| 1645 | 2 |
| 1641 | 2 |
| 1699 | 2 |
| 1628 | 1 |
| 1637 | 1 |
| 2189 | 1 |
| 1629 | 1 |
| 1651 | 1 |
| 1657 | 1 |
| 1619 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19423511 | CHIMERIC NEUROTOXINS | Ipsen Biopharm Limited | DUFFY, PATRICIA ANN | 1645 | §102§103§112Other | Non-Final OA | — | Pending | Dec 17, 2025 |
| 19341888 | CHIMERIC NEUROTOXINS | Ipsen Biopharm Limited | DUFFY, PATRICIA ANN | 1645 | §103§112Other | Non-Final OA | — | Pending | Sep 26, 2025 |
| 19086136 | FIVE-MEMBERED-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | Hangzhou Polymed Biopharmaceuticals, Inc. | MOU, LIYUAN | 1628 | §103§112Other | Final Rejection | 9d | Pending | Mar 21, 2025 |
| 18812463 | COMPOSITIONS AND METHODS FOR TREATMENT OF BLEEDING DISORDERS | Band Therapeutics, LLC | ANGELL, JON E | 1637 | §112DP | Non-Final OA | — | Pending | Aug 22, 2024 |
| 18599808 | FATTY ACID CONJUGATES OF NUCLEIC ACIDS | Guardian Therapeutics, LLC | HUDSON, AMY ROSE | §102§103§112 | Non-Final OA | — | Pending | Mar 08, 2024 | |
| 18573361 | METHOD OF PERFORMING A NUMERICAL SOLVING PROCESS | Talos Innovation Aps | GAN, CHUEN-MEEI | 2189 | §101§102§112 | Non-Final OA | — | Pending | Dec 21, 2023 |
| 18506625 | MACROCYCLIC COMPOUNDS AND USES THEREOF | Theseus Pharmaceuticals, Inc. | SHOWALTER, ALEXANDER KEITH | 1629 | §112 | Non-Final OA | 12d | Pending | Nov 10, 2023 |
| 18499051 | ANTIBODY MOLECULE FOR HUMAN GM-CSF RECEPTOR ALPHA | Zenyth Operations Pty. Ltd. | NATARAJAN, MEERA | §112 | Non-Final OA | — | Pending | Oct 31, 2023 | |
| 18552457 | CATALYTICALLY INACTIVE CLOSTRIDIAL NEUROTOXINS FOR THE TREATMENT OF PAIN & INFLAMMATORY DISORDERS | Ipsen Biopharm Limited | PAGUIO FRISING, MICHELLE F | 1651 | §102§103DP | Non-Final OA | — | Pending | Sep 26, 2023 |
| 18552599 | Clostridial Neurotoxins Comprising an Exogenous Activation Loop | Ipsen Biopharm Limited | BREEN, KIMBERLY CATHERINE | 1657 | §103§112DP | Non-Final OA | — | Pending | Sep 26, 2023 |
| 18258914 | HOMOGENEOUS BIOPOLYMER SUSPENSIONS, PROCESSES FOR MAKING SAME AND USES THEREOF | 11584022 Canada Inc. | BABSON, NICOLE PLOURDE | 1619 | §102§103§112Other | Final Rejection | 79d overdue | Pending | Jun 22, 2023 |
| 18253975 | COMPOSITIONS AND METHODS FOR TREATMENT OF BLEEDING DISORDERS | Band Therapeutics, LLC | NOAKES, SUZANNE MARIE | 1656 | §112DP | Non-Final OA | — | Pending | May 23, 2023 |
| 18248030 | BIOMARKERS, METHODS, AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASE INCLUDING SYSTEMIC LUPUS ERYTHEMATOUS (SLE) | Xencor, Inc. | DAHLE, CHUN WU | 1641 | §101§112 | Non-Final OA | — | Pending | Apr 05, 2023 |
| 18183588 | SELECTION OF RESPONDERS FOR ANTI-BTN3A TREATMENT | Imcheck Therapeutics SAS | ROONEY, NORA MAUREEN | 1641 | DP | Non-Final OA | — | Pending | Mar 14, 2023 |
| 18167529 | METHODS OF USING INTERLEUKIN-2 AGENTS | VISTERRA, INC. | CHATTIN, AMY MARIE | 1643 | §103 | Non-Final OA | — | Pending | Feb 10, 2023 |
| 18096899 | TREATMENT OF MODERATE TO VERY SEVERE GLABELLAR LINES AND LATERAL CANTHAL LINES | Ipsen Biopharm Limited | DAVIS, RUTH A | 1699 | §112DPOther | Final Rejection | 34d | Pending | Jan 13, 2023 |
| 17759674 | TREATMENT OF SKIN CONDITIONS | Ipsen Biopharm Limited | DAVIS, RUTH A | 1699 | §102§103§112Other | Non-Final OA | 40d | Pending | Jul 28, 2022 |
| 17782045 | SYNTHETIC GUIDE RNA, COMPOSITIONS, METHODS, AND USES THEREOF | Beam Therapeutics Lnc. | SPENCER, ANDREA LYNNE MORRIS | 1631 | §103 | Final Rejection | — | Pending | Jun 02, 2022 |
| 17776533 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | Praeventix, LLC | RICCI, CRAIG D | 1611 | DP | Final Rejection | 9d | Pending | May 12, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial